ROIV as of Oct 31 · 18:54 ET

ROIVNasdaqPharmaceutical Preparations

Roivant Sciences Ltd. · Brief

Next report

9 days

Nov 9 · before openest.Q2 FY26

Earnings

Expected move

Inputs

±9.5%implied · report alone

33.3940.43

straddle ±10.6%

spot 36.91exp Nov 20ATM strike 37ATM straddle 4.60IV 65%

Oct 30 closereport share · term structure

Expected move

Inputs

Implied vs realized

8 reportsHistory

—≥ implied

Feb 10 '25—▼−0.92%—

May 29 '25—▲+6.40%—

Aug 11 '25—▼−2.79%—

Q2 FY25—▲+2.67%—

Q3 FY25—▲+22.14%—

Q4 FY25—▲+1.76%—

May 20 '26—▲+14.89%—

Q1 FY26±8.4%▲+1.50%×0.18

quarterimplied−25%0+25%realized×

Q1 FY26±8.4%▲+1.50%×0.18

May '26—▲+14.89%—

Q4 FY25—▲+1.76%—

Q3 FY25—▲+22.14%—

Q2 FY25—▲+2.67%—

Aug '25—▼−2.79%—

2 older reports

May '25—▲+6.40%—

Feb '25—▼−0.92%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 9 report · est.

Bull2 of 3

6disclosed supplier and customer ties in SEC filingsSEC filings

497managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

10 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

34managers holding four fifths of reported value13F · Jun 30 '26

AI captions · Oct 26 '26once per report · top 2 per case

Linked exposure

ROIV report session

Customers 1

IMVTImmunovant×0.86

× = co-movement · max 500dSource: SEC filings · market data

Latest changes

30 daysAll changes

Oct 26impliedImplied move: ±10.7% into Nov 9 earnings (Oct 26 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.